Dalgety, a UK-based EU-GMP certified medical cannabis cultivator, has today announced a new strategic partnership with Curaleaf Laboratories, a trusted name in cannabis medicine and pharmaceutical-quality cannabinoid innovation.
This collaboration is a significant step towards ensuring affordable, safe, and sustainable access to high-quality medical cannabis in the UK.
As the UK medical cannabis sector grows, so too does the need to build a responsible, resilient domestic supply chain, one rooted in quality, transparency, and trust.
For Dalgety, that means working not only with the right partners but also with those whose own networks reflect the same high standards. This partnership with Curaleaf reflects a shared vision for safeguarding the integrity of the UK medical cannabis system at a time when bad actors threaten to undermine patient and clinician confidence.
“Our goal at Dalgety has always been to put patients first, delivering consistent, effective medicine.” said James Leavesley, CEO of Dalgety.
“But to do that, we must tackle non-patient derived costs that inflate prices and damage trust. This partnership with Curaleaf allows us to reduce unnecessary layers in the supply chain, while maintaining (and in many cases raising) standards across cultivation, manufacturing, and distribution.”
The collaboration brings together Dalgety’s UK-first cultivation with EU GMP credentials and Curaleaf’s global pharmaceutical expertise, creating a powerful framework for cost efficiency, supply chain transparency, and long-term market stability.
With both organisations aligned in their commitment to compliance, innovation and patient care, the partnership aims to help shape a future where UK patients can access legal cannabis-based medicines with confidence and dignity.
Richard Hodgson, Managing Director of Curaleaf Laboratories, said: “We are delighted to announce our
partnership with Dalgety, to provide a range of high quality EU-GMP products that have gone through a
full UK supply chain, from cultivation to manufacture and distribution.
“This partnership with a premium UK grower of EU-GMP medical cannabis again shows our
commitment towards widening access, with competitively priced products with a variety of strain
profiles and dosage forms.
“The addition of a fully UK produced range of medical cannabis products, aligns with our vision widening access across both healthcare professionals and patients. Our best-in-class distribution service ensures that specialist prescribers can prescribe with confidence to ensure a sustainable treatment plan for their patients.
“Dalgety stood-out as a producer that we really wanted to work with their EU-GMP licenses so we are extremely excited that we have been able to make this happen and we look forward to seeing how our partnership develops.”
Leavesley continued: “We’re focused on building something sustainable; not just commercially, but ethically,”
“That means working with people who share our values, our attention to detail, and our belief in what the UK cannabis industry should be. ”
Further announcements on the operational impact of the partnership will follow in the coming weeks.
Dalgety has also been shortlisted for ‘Producer of the Year’ at this year’s Business of Cannabis Awards on June 24th, taking place in London tomorrow night.
